Search Results

You are looking at 231 - 240 of 2,704 items for :

  • Refine by Access: All x
Clear All
Full access

Adjuvant Treatment in Non-Small Cell Lung Cancer: Where Are We Now?

Rosalyn A. Juergens and Julie R. Brahmer

-analysis using updated data on individual patients from 52 randomised clinical trials . Non-small Cell Lung Cancer Collaborative Group . BMJ 1995 ; 311 : 899 – 909 . 12. Postoperative radiotherapy in non-small-cell lung cancer: systemic review and

Full access

Current Role and Future Potential of CSF ctDNA for the Diagnosis and Clinical Management of Pediatric Central Nervous System Tumors

Alexandra M. Miller and Matthias A. Karajannis

– 31 Furthermore, CSF ctDNA detection has been associated with tumor proximity to the CSF space, tumor burden, active disease, and leptomeningeal spread of disease. 12 , 27 , 32 This review will focus on the studies to date performed on CSF ctDNA in

Full access

Cervical Cancer, Version 2.2015

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, Kathleen R. Cho, Christina Chu, David Cohn, Marta Ann Crispens, Oliver Dorigo, Patricia J. Eifel, Christine M. Fisher, Peter Frederick, David K. Gaffney, Ernest Han, Warner K. Huh, John R. Lurain III, David Mutch, Amanda Nickles Fader, Steven W. Remmenga, R. Kevin Reynolds, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Catheryn M. Yashar, Nicole R. McMillian, and Jillian L. Scavone

All clinicians completing this activity will be issued a certificate of participation. To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66

Full access

A Practice-Based Evaluation of Distress Screening Protocol Adherence and Medical Service Utilization

Brad Zebrack, Karen Kayser, Deborah Bybee, Lynne Padgett, Laura Sundstrom, Chad Jobin, and Julianne Oktay

-accredited US cancer centers (or similar designation in Canada). Anonymized patient data from electronic health records (EHRs) were reviewed to evaluate program compliance with CoC Standard 3.2 and the extent to which compliance on a case-by-case basis was

Full access

Extending Comprehensive Cancer Center Expertise in Clinical Cancer Genetics and Genomics to Diverse Communities: The Power of Partnership

Deborah J. MacDonald, Kathleen R. Blazer, and Jeffrey N. Weitzel

genetics ( Figure 2 ). The CSPPN and CGEP facilitate the integration of genetics services in the community and provide access to a robust program of laboratory and health services research through an institutional review board–approved Hereditary Cancer

Full access

Risk Factors for Development of Hypocalcemia in Patients With Cancer Treated With Bone-Modifying Agents

Paul S. White, Michael Dennis, Eric A. Jones, Janice M. Weinberg, and Shayna Sarosiek

a retrospective review of all individuals who received a BMA at Boston University School of Medicine and Boston Medical Center between January 1, 2005, and December 31, 2015. This study was approved by the Boston University Medical Center

Full access

Counterpoint: The Case Against Adjuvant High-Dose Interferon-α for Melanoma Patients

Paul B. Chapman

review of randomized controlled trials . J Clin Oncol 2002 ; 20 : 1818 – 1825 . 7 Kirkwood JM Ibrahim JG Sondak VK . High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 . J Clin

Full access

Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study

James Saller, Christine M. Walko, Sherri Z. Millis, Evita Henderson-Jackson, Rikesh Makanji, and Andrew S. Brohl

classic KS treated successfully with PD-1 inhibitor therapy. Next-generation sequencing (NGS)–based molecular testing was performed on a pretreatment tumor sample from this case. We review the clinical and immunogenomic findings in this patient, and

Full access

Unanswered Questions in the Management of Stage I-III Merkel Cell Carcinoma

Jonathan S. Zager, Jane L. Messina, L. Frank Glass, and Vernon K. Sondak

journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at ; and 4) view

Full access

NCCN Guidelines® Insights: Distress Management, Version 2.2023

Featured Updates to the NCCN Guidelines

Michelle B. Riba, Kristine A. Donovan, Kauser Ahmed, Barbara Andersen, IIana Braun, William S. Breitbart, Benjamin W. Brewer, Cheyenne Corbett, Jesse Fann, Stewart Fleishman, Sofia Garcia, Donna B. Greenberg, George F. Handzo Rev., Laura Herald Hoofring, Chao-Hui Huang, Sean Hutchinson, Shelley Johns, Jennifer Keller, Pallavi Kumar, Sheila Lahijani, Sara Martin, Shehzad K. Niazi, Megan Pailler, Francine Parnes, Vinay Rao, Jaroslava Salman, Eli Scher, Jessica Schuster, Melissa Teply, Angela Usher, Alan D. Valentine, Jessica Vanderlan, Megan S. Lyons, Nicole R. McMillian, and Susan D. Darlow

participation. To participate in this journal CE activity: (1) review the educational content; (2) take the posttest with a 66% minimum passing score and complete the evaluation at ; and (3) view/print certificate